Highlights of the American Academy of Neurology Annual Meeting
By Projects In Knowledge, Inc
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Listen as James D. Bowen, MD, and Augusto A. Miravalle, MD, review some of the most significant MS research presented at the 63rd AAN annual meeting, held April 9-16, 2011, in Honolulu, Hawaii. Dr. Bowen provides updates in the areas of pathology, immunology, genetics, testing, imaging, and cognitive dysfunction. Dr. Miravalle summarizes the latest data on current and emerging therapies.
||CleanEmerging Therapies||Data from AAN 2011 on emerging MS therapies, including laquinimod, cladribine, alemtuzumab, and more.||28 4 2011||Free||View in iTunes|
||CleanCurrent Therapies||Data from AAN 2011 on current MS therapies, including interferon beta, glatiramer acetate, natalizumab, mitoxantrone, and fingolimod.||28 4 2011||Free||View in iTunes|
||CleanCognitive Dysfunction||New research on MS-related cognitive dysfunction from AAN 2011.||28 4 2011||Free||View in iTunes|
||CleanTesting, Imaging, Biomarkers, and Predictors||Reports from AAN 2011 on evolving applications of imaging and testing in MS.||28 4 2011||Free||View in iTunes|
||CleanPathophysiology, Immunology, Genetics, Neuropreservation - Part 2||Latest research from AAN 2011 on mechanisms of disease progression in MS.||28 4 2011||Free||View in iTunes|
||CleanPathophysiology, Immunology, Genetics, Neuropreservation - Part 1||Latest research from AAN 2011 on risk factors for and pathogenesis of MS.||28 4 2011||Free||View in iTunes|